300 LITERATURE CASE SERIES REVIEW ON LANDIOLOL IN ACUTE DECOMPENSATED HEART FAILURE SECONDARY TO TACHYARRHYTHMIAS

Abstract Introduction Landiolol is a recently innovated ultra-short-acting beta-blocker. the only beta-blocker with specific dose recommendation for patients cardiac dysfunction and acute atrial fibrillation (Class I according to ESC guidelines). has shorter elimination half-life than any other beta-blocker, it can be administered safely various tachyarrhythmias. The short duration of action titratability landiolol makes ideal use in critically ill patients. Purpose Study Review case reports literature on administration decompensated heart failure (ADHF) secondary Methods 11 ADHF tachyarrhythmias were identified. Personal, clinical humoral data collected. rate systolic pressure values time before after plotted summary graph. Results mean age was 55 years old high proBNP at admission. etiological diagnosis heterogeneous but tachyarrhythmia trigger event all Patients EF 26 ± 16% an initial shock index 1.4 ±0.5. together antiarrhythmic drugs (amiodarone 4/11 patients), epinephrine/norepinephrine (9/11) levosimendan (4/11) favoured lowering increase blood pressure.At discharge, had improved EF, 10/11 sinus rhythm restored, recovered hemodynamic stability without adverse events related (Figure 1). Conclusion In this series review, useful strategy refractory conventional therapy by facilitating rate/rhythm control, limiting toxicity inotropic improving profile. Figure 1